51 patents currently held
95 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
35 more records may belong here and await a decision; they are not counted.
The next term ends in Dec 2026. from the record
Of the 95 now held by other companies, 35 name Ucb Biopharma SPRL as their current owner, and 60 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
26
Ending by 2030
Dec 2026
Next term end
30
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2032 · High confidence
Also notable
Ends Jun 2031 · High confidence
Also notable
Ends Sep 2032 · High confidence
Also notable
Ends Feb 2031 · High confidence
Also notable
Ends Feb 2031 · High confidence
Also notable
Ends Feb 2031 · High confidence
Also notable
Ends Sep 2030 · High confidence
Also notable
Ends Jul 2031 · High confidence
Polyvinylpyrrolidone for the Stabilization of a Solid Dispersion of the Non-Crystalline Form of Rotigotine
US 9,925,150
Cited by 13 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Bacterial Host Strain
US 9,109,216
Cited by 22 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Protein Purification
US 9,309,280
The largest patent family in this portfolio, 5 related applications, renewed at every maintenance window due so far. Protection runs to 2032.
Bacterial Host Strain Expressing Recombinant DSBC and Having Reduced TSP Activity
US 8,969,038
The most cited patent in this portfolio, cited by 23 later US patents, top 25% of utility patents granted in 2015 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Bacterial Host Strain Comprising a Mutant SPR Gene and Having Reduced TSP Activity
US 8,969,039
The most cited patent in this portfolio, cited by 23 later US patents, top 25% of utility patents granted in 2015 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Bacterial Host Strain Comprising a Mutant SPR Gene and a Wild-Type TSP Gene
US 8,969,037
Cited by 22 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Bacterial Host Strain Expressing Recombinant DSBC
US 9,725,516
Cited by 13 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Process for Purifying Proteins
US 9,751,930
Cited by 15 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Formerly held, still cited
Notable
Ends Feb 2029 · High confidence
Cited by 62 later US patents, top 10% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
now held by Ucb Biopharma SRL
Also notable
Ends Jun 2032 · High confidence
Cited by 17 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2032.
now held by Ucb Developed Brands SRL
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 16 to 25, 2027 · next Jan 16
- 1 fee due Feb 18, 2027The maintenance fee for Bacterial Host Strain (US 9,109,216) comes due Feb 18, 2027. Unpaid by Aug 18, 2027, it lapses early.
- 1 fee due May 21, 2027The maintenance fee for Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides (US 11,820,746) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 1 fee due Jun 26, 2027The maintenance fee for Anti-Sclerostin Antibodies and Their Use to Treat Bone Disorders as Part of a Regimen (US 11,851,483) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
- 1 fee due Aug 13, 2027The maintenance fee for Treatment for Bone Diseases (US 11,896,667) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
- 1 fee due Sep 26, 2027The maintenance fee for Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides (US 11,939,319) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
- 2 fees due Oct 12 to 19, 2027 · next Oct 12
- 1 fee due Nov 7, 2027The maintenance fee for Substituted Alkoxypyridinyl Indolsulfonamides (US 11,976,056) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- 4 terms have ended since Aug 23, 2026
- Nov 20 US 10,130,589 Polyvinylpyrrolidone for the Stabilization of a Solid Dispersion of the Non-Crystalline Form of Rotigotine · lapsed on the fee record
- Oct 9 US 10,093,652 Tetrahydrobenzimidazole Derivatives as Modulators of TNF Activity · lapsed on the fee record
- Oct 2 US 10,087,179 Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity · lapsed on the fee record
- Sep 9 US 8,828,719 Method for Producing Protein · lapsed on the fee record
What they patent
The largest of its 30 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,670,621 | Transdermal Administration of (R)-3,3-Diphenylpropylamin-MONOESTERS In force · High confidence | In force | High confidence | |
| US 8,604,051 | Thieno-Pyridine Derivatives as Mek Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 9,309,215 | Chiral Intermediate, Process for Producing the Same and Its Use in the Manufacture of Tolterodine, Fesoterodine, or the Active Metabolite Thereof In force · Low confidence | In force | Low confidence | |
| US 7,807,715 | Pharmaceutical Compositions Comprising Fesoterodine In force · High confidence | In force | High confidence | |
| US 9,364,541 | Pharmaceutical Compositions Comprising Fesoterodine In force · Medium confidence | In force | Medium confidence | |
| US 9,095,557 | Anticonvulsant Combination Therapy In force · Medium confidence | In force | Medium confidence | |
| US 9,446,011 | Anticonvulsant Combination Therapy In force · High confidence | In force | High confidence | |
| US 7,982,058 | Chiral Intermediate, Process for Producing the Same and Its Use in the Manufacture of Tolterodine, Fesoterodine, or the Active Metabolite Thereof In force · High confidence | In force | High confidence | |
| US 8,969,036 | Process for Obtaining Antibodies In force · High confidence | In force | High confidence | |
| US 8,246,979 | Transdermal Delivery System for the Administration of Rotigotine In force · High confidence | In force | High confidence |
Also on record, not counted in the 51: 95 patents in force now held by others · 243 patents ended · 19 applications pending · 130 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.